简体中文

Plinabulin

  • Triple Combos

  • Plinabulin + nivolumab + ipilimumab

    In collaboration with Bristol Myers Squibb, we commenced an investigator-initiated Phase 1/2 trial of Plinabulin at Rutgers University in combination with Opdivo (nivolumab), a PD-1 antibody, and Yervoy (ipilimumab), a CTLA-4 antibody, as a treatment for small cell lung cancer (SCLC). This study investigates whether the addition of Plinabulin results in a reduction of immune-related side effects of PD-1 and CTLA-4 antibodies and provides efficacy synergy.

  • Plinabulin + pembrolizumab + chemo

    In collaboration with Merck, we commenced an investigator-initiated Phase 1/2 trial of Plinabulin at Johns Hopkins University in combination with Keytruda (pembrolizumab), a PD-1 antibody, and platinum-based chemotherapy agents as a first-line treatment for NSCLC. This study investigates whether the addition of Plinabulin results in a reduction of immune-related side effects of PD-1 antibodies and a reduction in severe neutropenia caused by platinum-based chemotherapy.

  • Clinical Trials

    For details of these two trials, please visit below websites.

    A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients with Recurrent Small Cell Lung Cancer

© BeyondSpring Inc. All Rights Reserved.